Cargando…

Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer

Cetuximab is a common treatment option for patients with wild-type K-Ras colorectal carcinoma. However, patients often display intrinsic resistance or acquire resistance to cetuximab following treatment. Here we generate two human CRC cells with acquired resistance to cetuximab that are derived from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zulkifli, Ahmad, Tan, Fiona H., Areeb, Zammam, Stuart, Sarah F., Gomez, Juliana, Paradiso, Lucia, Luwor, Rodney B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269417/ https://www.ncbi.nlm.nih.gov/pubmed/34281166 http://dx.doi.org/10.3390/ijms22137114

Ejemplares similares

Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma
por: Areeb, Zammam, et al.
Publicado: (2020)

EGFRvIII Promotes Cell Survival during Endoplasmic Reticulum Stress through a Reticulocalbin 1-Dependent Mechanism
por: Gomez, Juliana, et al.
Publicado: (2021)

The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis
por: Stuart, Sarah F., et al.
Publicado: (2023)

Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression
por: Ma, Chenkai, et al.
Publicado: (2022)

Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth
por: Tan, Fiona H., et al.
Publicado: (2018)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
por: Li, Qian, et al.
Publicado: (2018)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy
por: Hsu, Chin-Mu, et al.
Publicado: (2022)

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2016)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
por: Tan, Fiona H, et al.
Publicado: (2019)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker
por: Ma, Chenkai, et al.
Publicado: (2018)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response
por: Vangala, Janakiram R., et al.
Publicado: (2020)

Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs
por: Whitehead, Clarissa A., et al.
Publicado: (2018)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

PTEN status in advanced colorectal cancer treated with cetuximab
por: Negri, F V, et al.
Publicado: (2010)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

P857: BORTEZOMIB- AND CARFILZOMIB-RESISTANT MYELOMA CELLS SHOW INCREASED ACTIVITY OF ALL THREE ARMS OF UNFOLDED PROTEIN RESPONSE AND ENRICHMENT OF SIRTUIN SIGNALING PATHWAY
por: Kubicki, T., et al.
Publicado: (2022)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
por: Han, Bo, et al.
Publicado: (2015)

Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells
por: Lee, Song-I, et al.
Publicado: (2019)

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
por: Shi, Yonghua, et al.
Publicado: (2016)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
por: Eigbire-Molen, Odianosen, et al.
Publicado: (2022)

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
por: Philipponnet, Carole, et al.
Publicado: (2022)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
por: Barla, Ioanna, et al.
Publicado: (2022)

Unfolded protein response in colorectal cancer
por: Huang, Jingjing, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis
por: Neyns, B., et al.
Publicado: (2008)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
por: Dahan, Laetitia, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pld6006hgtrctbqhuo73u39cbq